Canakinumab (ILARIS®), an IL-1 inhibitor, is a high-affinity, fully humanized monoclonal anti-IL-1β antibody approved for the treatment of CAPS, systemic juvenile idiopathic arthritis, and other periodic fever syndromes [98]. The gene discussed is IL1B; the disease is systemic-onset juvenile idiopathic arthritis.